US FDA approves Incyte’s merkel cell carcinoma therapy
Pharmaceutical Technology
MARCH 23, 2023
It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. We continue to study the potential of Zynyz in additional tumour types and in combination with other Incyte pipeline compounds.”
Let's personalize your content